LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Labanca, Caterina"
  2. AU=Patel Shikha AU=Patel Shikha

Suchergebnis

Treffer 1 - 10 von insgesamt 15

Suchoptionen

  1. Artikel ; Online: Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies.

    Bruzzese, Antonella / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on investigational drugs

    2024  Band 33, Heft 2, Seite(n) 73–77

    Mesh-Begriff(e) Humans ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/pathology ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Proto-Oncogene Proteins c-bcl-2
    Chemische Substanzen Antineoplastic Agents ; Proto-Oncogene Proteins c-bcl-2 ; BCL2 protein, human
    Sprache Englisch
    Erscheinungsdatum 2024-01-26
    Erscheinungsland England
    Dokumenttyp Editorial
    ZDB-ID 1182884-5
    ISSN 1744-7658 ; 0967-8298 ; 1354-3784
    ISSN (online) 1744-7658
    ISSN 0967-8298 ; 1354-3784
    DOI 10.1080/13543784.2024.2309873
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3739: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Momelotinib in myelofibrosis.

    Bruzzese, Antonella / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Zimbo, Annamaria / Fragliasso, Valentina / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2024  , Seite(n) 1–8

    Abstract: Introduction: Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, ...

    Abstract Introduction: Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence, and even worsening anemia remains a significant challenge, leading usually to treatment discontinuation.
    Areas covered: This review focuses on Momelotinib (MMB), a unique JAK inhibitor that has shown promise in MF treatment, particularly in improving anemia. MMB inhibits type 1 kinase activin A receptor or activin receptor-like kinase-2 (ACVR1/ALK2), with consequent rebalancing of the SMAD pathways and reduced transcription of hepcidin. Moreover, it seems that MMB could reduce the serum levels of several inflammatory cytokines responsible for anemia. Clinical trials have demonstrated MMB's efficacy in reducing spleen size, alleviating symptoms, and improving anemia, with a favorable safety profile compared to other JAK inhibitors, both in treatment-naïve and in pre-treated patients.
    Expert opinion: Due to its mechanism of action, MMB represents a valuable therapeutic option in MF, addressing the clinical challenge of anemia and potentially improving outcomes for patients with hematologic malignancies. Ongoing research explores MMB's potential in acute myeloid leukemia and combination therapies.
    Sprache Englisch
    Erscheinungsdatum 2024-04-18
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2024.2343780
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5130: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Selinexor in multiple myeloma.

    Martino, Enrica Antonia / Vigna, Ernesto / Bruzzese, Antonella / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Zimbo, Annamaria / Torricelli, Federica / Neri, Antonino / Morabito, Fortunato / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2024  Band 25, Heft 4, Seite(n) 421–434

    Abstract: Introduction: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).: Areas covered: This article provides a review of selinexor, with a focus on ... ...

    Abstract Introduction: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).
    Areas covered: This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile. Clinical trials, such as STORM and BOSTON, have demonstrated its efficacy, particularly in combination regimens, showcasing notable overall response rates (ORR) and prolonged median progressionfree survival (mPFS). Selinexor's versatility is evident across various combinations, including carfilzomibdexamethasone (XKd), lenalidomidedexamethasone (XRd), and pomalidomidedexamethasone (XPd), with efficacy observed even in tripleclass refractory and highrisk patient populations. However, challenges, including resistance mechanisms and adverse events, necessitate careful management. Realworld evidence also underscores selinexor's effectiveness in RRMM, though dose adjustments and supportive measures remain crucial. Ongoing trials are exploring selinexor in diverse combinations and settings, including pomalidomidenaïve patients and postautologous stem cell transplant (ASCT) maintenance.
    Expert opinion: The evolving landscape of selinexor's role in the sequencing of treatment for RRMM, its potential in highrisk patients, including those with extramedullary disease, as revealed in the most recent international meetings, and ongoing investigations signal a dynamic era in myeloma therapeutics. Selinexor emerges as a pivotal component in multidrug strategies and innovative combinations.
    Mesh-Begriff(e) Multiple Myeloma/drug therapy ; Humans ; Hydrazines/therapeutic use ; Hydrazines/adverse effects ; Triazoles/therapeutic use ; Triazoles/adverse effects ; Karyopherins/antagonists & inhibitors ; Exportin 1 Protein ; Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Progression-Free Survival
    Chemische Substanzen selinexor (31TZ62FO8F) ; Hydrazines ; Triazoles ; Karyopherins ; Exportin 1 Protein ; Receptors, Cytoplasmic and Nuclear ; Antineoplastic Agents
    Sprache Englisch
    Erscheinungsdatum 2024-03-25
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2024.2333376
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5130: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Ivosidenib in acute myeloid leukemia.

    Bruzzese, Antonella / Labanca, Caterina / Martino, Enrica Antonia / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Imovilli, Annalisa / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2024  Band 24, Heft 18, Seite(n) 2093–2100

    Abstract: Introduction: Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substantially in recent years, mainly due to the ... ...

    Abstract Introduction: Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substantially in recent years, mainly due to the introduction of hypomethylating agents and small molecules.Bcl2 inhibitor venetoclax, Fms-like tyrosine kinase 3 (FLT3) inhibitors such as midostaurin and gilteritinib, and isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) inhibitors ivosidenib and enasidenib, as well as hedgehog (HH) pathway inhibitor glasdegib represented a significant step forward in AML therapeutic armamentarium. Smoothened (SMO) inhibitor in combination with low-dose cytarabine marks a recent milestone.
    Areas covered: Ivosidenib, the first-in-class, selective, allosteric IDH1R132 inhibitor, showed the capability to induce
    Expert opinion: The identified ivosidenib's strengths, including its remarkable safety record and ability to yield positive therapeutic outcomes, position it as an ideal partner for both classic chemotherapy and biological treatments, i.e. hypometilant agents and/or venetoclax. Further studies are warranted to explore strategies for overcoming the occurrence of ivosidenib resistance.
    Mesh-Begriff(e) Humans ; Hedgehog Proteins ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/metabolism ; Pyridines/adverse effects ; Antineoplastic Agents/adverse effects ; Mutation
    Chemische Substanzen ivosidenib (Q2PCN8MAM6) ; venetoclax (N54AIC43PW) ; Hedgehog Proteins ; Pyridines ; Antineoplastic Agents
    Sprache Englisch
    Erscheinungsdatum 2024-01-05
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2272659
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5130: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia.

    Bruzzese, Antonella / Vigna, Ernesto / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Stanzione, Gaia / Zimbo, Annamaria / Lugli, Elisabetta / Neri, Antonino / Morabito, Fortunato / Gentile, Massimo

    Expert review of hematology

    2024  , Seite(n) 1–13

    Abstract: Introduction: Acute myeloid leukemia (AML) encompasses a heterogeneous group of aggressive myeloid malignancies, where FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent, accounting for approximately 25-30% of adult patients. The presence of this ...

    Abstract Introduction: Acute myeloid leukemia (AML) encompasses a heterogeneous group of aggressive myeloid malignancies, where FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent, accounting for approximately 25-30% of adult patients. The presence of this mutation is related to a dismal prognosis and high relapse rates. In the lasts years many FLT3 inhibitors have been developed.
    Areas covered: This review provides a comprehensive overview of FLT3
    Expert opinion: In addition, the review discusses the emergence of drug resistance and the need for a nuanced approaches in treating patients who are ineligible for or resistant to intensive chemotherapy. Specifically, it explores the historical context of FLT3 inhibitors (FLT3Is) and their impact on treatment outcomes, emphasizing the pivotal role of midostaurin, as well as gilteritinib and quizartinib, and providing detailed insights into ongoing trials exploring the safety and efficacy of novel triplet combinations involving FLT3Is in different AML settings.
    Sprache Englisch
    Erscheinungsdatum 2024-05-20
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2516804-6
    ISSN 1747-4094 ; 1747-4086
    ISSN (online) 1747-4094
    ISSN 1747-4086
    DOI 10.1080/17474086.2024.2356258
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6943: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.

    Staropoli, Nicoletta / Scionti, Francesca / Farenza, Valentina / Falcone, Federica / Luciano, Francesco / Renne, Maria / Di Martino, Maria Teresa / Ciliberto, Domenico / Tedesco, Ludovica / Crispino, Antonella / Labanca, Caterina / Cucè, Maria / Esposito, Stefania / Agapito, Giuseppe / Cannataro, Mario / Tassone, Pierfrancesco / Tagliaferri, Pierosandro / Arbitrio, Mariamena

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2024  Band 174, Seite(n) 116478

    Abstract: Background: Long-term survival induced by anticancer treatments discloses emerging frailty among breast cancer (BC) survivors. Trastuzumab-induced cardiotoxicity (TIC) is reported in at least 5% of HER2+BC patients. However, TIC mechanism remains ... ...

    Abstract Background: Long-term survival induced by anticancer treatments discloses emerging frailty among breast cancer (BC) survivors. Trastuzumab-induced cardiotoxicity (TIC) is reported in at least 5% of HER2+BC patients. However, TIC mechanism remains unclear and predictive genetic biomarkers are still lacking. Interaction between systemic inflammation, cytokine release and ADME genes in cancer patients might contribute to explain mechanisms underlying individual susceptibility to TIC and drug response variability. We present a single institution case series to investigate the potential role of genetic variants in ADME genes in HER2+BC patients TIC experienced.
    Methods: We selected data related to 40 HER2+ BC patients undergone to DMET genotyping of ADME constitutive variant profiling, with the aim to prospectively explore their potential role in developing TIC. Only 3 patients ("case series"), who experienced TIC, were compared to 37 "control group" matched patients cardiotoxicity-sparing. All patients underwent to left ventricular ejection fraction (LVEF) evaluation at diagnosis and during anti-HER2 therapy. Each single probe was clustered to detect SNPs related to cardiotoxicity.
    Results: In this retrospective analysis, our 3 cases were homogeneous in terms of clinical-pathological characteristics, trastuzumab-based treatment and LVEF decline. We identified 9 polymorphic variants in 8 ADME genes (UGT1A1, UGT1A6, UGT1A7, UGT2B15, SLC22A1, CYP3A5, ABCC4, CYP2D6) potentially associated with TIC.
    Conclusion: Real-world TIC incidence is higher compared to randomized clinical trials and biomarkers with potential predictive value aren't available. Our preliminary data, as proof of concept, could suggest a predictive role of pharmacogenomic approach in the identification of cardiotoxicity risk biomarkers for anti-HER2 treatment.
    Mesh-Begriff(e) Humans ; Female ; Trastuzumab/adverse effects ; Trastuzumab/pharmacokinetics ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Cardiotoxicity/genetics ; Middle Aged ; Retrospective Studies ; Polymorphism, Single Nucleotide ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/pharmacokinetics ; Aged ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Adult
    Chemische Substanzen Trastuzumab (P188ANX8CK) ; Antineoplastic Agents, Immunological ; Receptor, ErbB-2 (EC 2.7.10.1)
    Sprache Englisch
    Erscheinungsdatum 2024-03-27
    Erscheinungsland France
    Dokumenttyp Journal Article
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2024.116478
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ud II Zs.198: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Belantamab mafodotin in multiple myeloma.

    Martino, Enrica Antonia / Bruzzese, Antonella / Iaccino, Enrico / Labanca, Caterina / Mendicino, Francesco / Mimmi, Selena / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on biological therapy

    2023  Band 23, Heft 11, Seite(n) 1043–1047

    Mesh-Begriff(e) Humans ; Multiple Myeloma/drug therapy ; Antibodies, Monoclonal, Humanized
    Chemische Substanzen belantamab mafodotin (DB1041CXDG) ; Antibodies, Monoclonal, Humanized
    Sprache Englisch
    Erscheinungsdatum 2023-05-27
    Erscheinungsland England
    Dokumenttyp Editorial
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2023.2218543
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6094: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: Tagraxofusp in myeloid malignancies.

    Bruzzese, Antonella / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Imovilli, Annalisa / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Hematological oncology

    2023  Band 42, Heft 1, Seite(n) e3234

    Abstract: Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with ... ...

    Abstract Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease that is usually refractory to conventional chemotherapy. Tagraxofusp had an acceptable safety profile and high efficacy in early phase I/II studies on patients with BPDCN. Another phase II study confirmed the good response rates, resulting in Food and Drugs Administration and European Medicine Agency approval of tagraxofusp for the treatment of BPDCN. Considering its high efficacy and its manageable safety profile, tagraxofusp has been suddenly explored in other myeloid malignancies with high expression of cell surface CD123, both in monotherapy or combination strategies. The triplet tagraxofusp-azacytidine-venetoclax appears to be of particular interest among these combinations. Furthermore, combination strategies may be used to overcome tagraxofusp resistance. The downregulation of DPH1 (diphthamide biosynthesis 1), the enzyme responsible for the conversion of histidine 715 on eEF2 to diphthamide, which is then the direct target of ADP ribosylation DT, is typically associated with this resistance phenomenon. It has been discovered that azacitidine can reverse DHP1 expression and restore sensitivity to tagraxofusp. In conclusion, the success of tagraxofusp in BPDCN paved the way for its application even in other CD123-positive malignancies. Nowadays, several ongoing trials are exploring the use of tagraxofusp in different myeloid neoplasms. This review aims to summarize the actual role of tagraxofusp in BPDCN and other CD123-positive myeloid malignancies.
    Mesh-Begriff(e) Humans ; Interleukin-3 Receptor alpha Subunit/metabolism ; Interleukin-3 Receptor alpha Subunit/therapeutic use ; Dendritic Cells/pathology ; Azacitidine/therapeutic use ; Myeloproliferative Disorders/pathology ; Acute Disease ; Skin Neoplasms/pathology ; Hematologic Neoplasms/pathology ; Clinical Trials, Phase II as Topic ; Recombinant Fusion Proteins
    Chemische Substanzen tagraxofusp (8ZHS5657EH) ; Interleukin-3 Receptor alpha Subunit ; Azacitidine (M801H13NRU) ; Recombinant Fusion Proteins
    Sprache Englisch
    Erscheinungsdatum 2023-10-17
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3234
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1816: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel ; Online: Glasdegib for the treatment of acute myeloid leukemia.

    Bruzzese, Antonella / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Fimognari, Filippo / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2023  Band 24, Heft 14, Seite(n) 1537–1543

    Abstract: Introduction: Over the last few years, substantial progress has been made in the management of acute myeloid leukemia (AML). The first changes in the management of AML date back to last 2000s with the advent of hypometilant agents, later with Bcl2 ... ...

    Abstract Introduction: Over the last few years, substantial progress has been made in the management of acute myeloid leukemia (AML). The first changes in the management of AML date back to last 2000s with the advent of hypometilant agents, later with Bcl2 inhibitor venetoclax, and Fms-like tyrosine kinase 3 (FLT3) inhibitors (midostaurin and gilteritinib), and more recently with IDH1/2 inhibitors (ivosidenib and enasidenib) and the hedgehog (HH) pathway inhibitor glasdegib.
    Areas covered: Glasdegid, formerly PF-04449913 or PF-913, acts as a smoothened (SMO) inhibitor and has been recently approved in combination with low-dose cytarabine (LDAC) by FDA and EMA for the treatment of naïve AML patients unfit for intensive chemotherapy.Several studies have explored the efficacy and safety of glasdegib, as a single agent or in combination with other drugs, in both the setting of relapsed/refractory and naïve AML patients, confirming its efficacy in controlling disease and safety profile.
    Expert opinion: All these trials suggest that glasdegib seems to be an ideal partner for both classic chemotherapy and biological treatments (such as therapy with FLT3 inhibitors). Further studies are needed to better understand which patients are more likely to respond to glasdegib.
    Mesh-Begriff(e) Humans ; Hedgehog Proteins ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/metabolism ; Benzimidazoles/therapeutic use ; Phenylurea Compounds/adverse effects ; Antineoplastic Agents/adverse effects
    Chemische Substanzen glasdegib (K673DMO5H9) ; Hedgehog Proteins ; Benzimidazoles ; Phenylurea Compounds ; Antineoplastic Agents
    Sprache Englisch
    Erscheinungsdatum 2023-07-03
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2232301
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5130: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel ; Online: Zanubrutinib for the treatment of chronic lymphocytic leukemia.

    Bruzzese, Antonella / Martino, Enrica Antonia / Labanca, Caterina / Mendicino, Francesco / Lucia, Eugenio / Olivito, Virginia / Neri, Antonino / Morabito, Fortunato / Vigna, Ernesto / Gentile, Massimo

    Expert opinion on pharmacotherapy

    2023  Band 24, Heft 13, Seite(n) 1409–1413

    Mesh-Begriff(e) Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects ; Piperidines/therapeutic use ; Protein Kinase Inhibitors/adverse effects
    Chemische Substanzen zanubrutinib (AG9MHG098Z) ; Pyrazoles ; Pyrimidines ; Piperidines ; Protein Kinase Inhibitors
    Sprache Englisch
    Erscheinungsdatum 2023-06-26
    Erscheinungsland England
    Dokumenttyp Editorial
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2229734
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5130: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang